5 Most Profitable Biotech Stocks Today

4. Merck & Co., Inc. (NYSE:MRK)

Net Income TTM: $14.51 billion

Founded in 1981, Merck & Co., Inc. (NYSE:MRK) is an American pharmaceutical company. In April 2021, Merck purchased Pandion Therapeutics, Inc., a clinical-stage biotech company focused on developing innovative therapies to address the needs of people living with autoimmune diseases. Merck & Co., Inc. (NYSE:MRK) has also formed a partnership with Gilead Sciences, Inc. to co-develop and market long-acting HIV treatments.

On February 02, 2023, Merck & Co., Inc. (NYSE:MRK) announced its Q4 2022 results, reporting revenue of $13.83 billion, surpassing analysts’ projections by $174 million. Additionally, the company’s Normalized EPS was reported at $1.62, exceeding Wall Street’s estimates by $0.08.

According to Insider Monkey’s database, 77 hedge funds held stakes worth $5.1 billion in Merck & Co., Inc. (NYSE:MRK) in Q4 2022, compared to 82 funds in the prior quarter with stake worth $4.7 billion.